Biotech

All Articles

Amgen reports first phase 3 gain for $400M eczema drug

.Amgen has shared (PDF) the initial stage 3 data on its own $400 million eczema medication, connecti...

Biogen, UCB file stage 3 lupus succeed after failing earlier trial

.Biogen and also UCB's bet one's bottom dollar developing right into stage 3 on the back of an unsuc...

Aptadir hopes brand-new RNA inhibitors can reverse tricky cancers

.Italian biotech Aptadir Rehabs has actually introduced along with the commitment that its own pipe ...

Wave surfs DMD effectiveness to regulators' doors, sending stock up

.Surge Life Sciences has actually met its own goal in a Duchenne muscular dystrophy (DMD) research, ...

Sanofi plucks brand new CSO from in-stealth biotech

.After a few years in biotech, Mike Quigley, Ph.D., is actually returning to the pharma crease, occu...

Achilles trickles cell therapy plan, bandages for layoffs after missing out on 'business stability' targets

.Achilles Therapeutics has destroyed its own tactic. The British biotech is actually knocking off on...

Aligos advertises phase 2 MASH gain, slashing liver body fat approximately 46%

.Aligos Therapies is proclaiming a midstage win in metabolic-dysfunction affiliated steatohepatitis ...

Basilea credit ratings $268M BARDA funding for antifungals, anti-biotics

.Basilea Pharmaceutica's work establishing brand-new antifungals has acquired a notable increase fro...

Capricor offers Europe legal rights to late-stage DMD treatment for $35M

.Having already gathered up the U.S. rights to Capricor Therapies' late-stage Duchenne muscular dyst...

FDA fragments adcomm for Applied's uncommon illness medication

.After dismissing the selection date for Applied Therapies' metabolic condition medicine govorestat,...